The Research Practitioner, May/June 2017
Changes in oncology treatments may lead to changes in clinical trial design: An overview of a basket trial in progress
As technology and science have evolved over the last several years, new treatment modalities for cancer have emerged. These new treatment options have presented a challenge for researchers. How do we translate new scientific advancements to patient populations rapidly and effectively, especially in oncology? Arguments that the drug development process is “broken” have stimulated improvements in clinical trial designs.1 One category of clinical trial design that has emerged as a result is a master protocol. Several designs fall under the master protocol category.
Disclosures bring continued focus to Bial trial
Last year, two issues of Research Practitioner included a discussion about a French trial in which one healthy volunteer died and five others were hospitalized. Researchers and pharmacologists are becoming more critical of the trial as new information become available. Were the researchers negligent? Why was this compound chosen over other similar ones for the study?
To read the full articles for this issue of Research Practitioner, please click here for subscription information.